Dr. Paul Nunzio DeSantis, Pharm.D
Event-driven, research analyst, hedge fund analyst, biotech

The Short Story Of Intercept Pharmaceuticals (Part I): A Conference Call With Expert Physicians

This article will be the first contribution in a series of reports that will track the rapid developments at Intercept Pharmaceuticals (NASDAQ:ICPT) throughout 2014. This report will only cover the most recent developments and summarize expert commentary regarding OCA from a conference call this past weekend. A more comprehensive report will be written when full top-line data from the FLINT trial and other trials are released. Once this data becomes available, it will provide insight into how OCA alters the pathogenesis of NASH. Depending on OCA's pharmacodynamic properties (what the drug does to the body), we can then construct a sales model and compare it to Wall Street's expectations. Future reports will provide a comprehensive overview of Intercept's...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
PRO Top long ideas returned 21.7% in 2016**
"As a PRO member, we get uniquely valuable perspective that go beyond our quantiative analysis... We rely on PRO to get beyond the numbers quickly and add much needed perspective. It keeps me ahead of the next big thing. - Mark Choate, Malaga Cove Capital"
Mark Choate, Malaga Cove Capital
"Contributors (writers and commentators), often have a long history in the secuirities they opine on and some are clearly well positioned industry participants with detailed industry views that can help provide color on where the skeletons are buried in a particular secuirity and/or industry."
Jim Roumell, Roumell Asset Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details